A
Anna Patrikidou
Researcher at Sarah Cannon Research Institute
Publications - 78
Citations - 2019
Anna Patrikidou is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 20, co-authored 65 publications receiving 1559 citations. Previous affiliations of Anna Patrikidou include University College Hospital & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Yohann Loriot,Diletta Bianchini,E. Ileana,Shahneen Sandhu,Anna Patrikidou,Carmel Pezaro,Laurence Albiges,Gerhardt Attard,Karim Fizazi,J.S. de Bono,Christophe Massard +10 more
TL;DR: Abiraterone and prednisolone have modest antitumour activities in patients with mCRPC pretreated with docetaxel and enzalutamide.
Journal ArticleDOI
Bisphosphonate-Related Osteonecrosis of the Jaws: A Case-Control Study of Risk Factors in Breast Cancer Patients
Athanassios Kyrgidis,Konstantinos Vahtsevanos,Georgios Koloutsos,C. Andreadis,Ioannis Boukovinas,Zisis Teleioudis,Anna Patrikidou,Stefanos Triaridis +7 more
TL;DR: Early referral by oncologists for dental evaluation for every patient to be treated with BP is suggested, and results indicate that history of tooth extraction during zoledronic acid treatment and the use of dentures increase the risk of developing ONJ.
Journal ArticleDOI
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
Christina Befani,Panagiotis J. Vlachostergios,Eleana Hatzidaki,Anna Patrikidou,Sophia Bonanou,George Simos,Christos N. Papandreou,Panagiotis Liakos +7 more
TL;DR: Results suggest that bortezomib inhibits HIF-1α protein synthesis and its nuclear targeting through suppression of PI3K/Akt/mTOR and MAPK pathways, respectively, in both AD and AI PCa cells.
Journal ArticleDOI
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival
Antoine Italiano,Maud Toulmonde,Angela Cioffi,Nicolas Penel,N. Isambert,Emmanuelle Bompas,Florence Duffaud,Anna Patrikidou,Barbara Lortal,A. Le Cesne,J.-Y. Blay,Robert G. Maki,Robert G. Maki,Gary K. Schwartz,C. R. Antonescu,Samuel Singer,J.-M. Coindre,Binh Bui +17 more
TL;DR: Chemotherapy was associated with clinical benefit in 46% of patients with advanced WDLPS/DDLPS, and OS remains poor, even though visceral metastatic disease is less frequent than in other sarcomas.
Journal ArticleDOI
Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival.
Athanassios Kyrgidis,Thrasivoulos Tzellos,N. Kechagias,Anna Patrikidou,P. Xirou,Kyriaki Kitikidou,Eleni Bourlidou,Konstantinos Vahtsevanos,Konstantinos Antoniades +8 more
TL;DR: Certain clinico-pathological predictors can be used to discriminate subsets of high-risk patients that could benefit from long-term follow-up and pT and N-stage, inflammation and perineural involvement were significant predictors for recurrence-free survival.